AEterna Zentaris
1405 Boul Du Parc-technologique
Quebec
G1P 4P5
Canada
Tel: 418-652-8525
Fax: 418-652-0881
Website: http://www.aeternazentaris.com/
Email: aeterna@aeternazentaris.com
644 articles about AEterna Zentaris
-
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
7/29/2020
Aeterna Zentaris Inc. announced that on July 27, 2020, the Company received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s common stock for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5550.
-
Aeterna Zentaris Announces Closing Of $12 Million Public Offering
7/7/2020
Aeterna Zentaris Inc., a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced the closing of its previously announced public offering of 17,544,516 units at a price to the public of $0.45 per unit and 9,122,150 pre-funded units at a price to the public of $0.4499 per pre-funded unit.
-
AETERNA ZENTARIS ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING
7/1/2020
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the pricing of a public offering of 26,666,666 units at a price to the public of $0.45 per unit,
-
AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY
6/25/2020
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an exclusive distribution and related quality agreement (the “Agreement”) with Megapharm Ltd. (“Megapharm”), a leading Israel-based biopharmaceutical company, for the commercialization in Israel and the Palestinian Authority of m
-
Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement - June 08, 2020
6/8/2020
Aeterna Zentaris Inc. announced that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of the Company’s common stock has been at $1.00 or greater for 10 consecutive trading days.
-
Aeterna Zentaris Announces Virtual 2020 Annual Meeting of Shareholders
5/8/2020
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced its Annual General Meeting (“AGM”) will be held on May 15, 2020 at 10:00 a.m. ET. Due to the impact of the COVID-19 pandemic, the meeting will be held virtually. Shareholders will not be able to attend the AGM in-person at a physical location. Ho
-
Aeterna Zentaris Reports First Quarter 2020 Financial and Operating Results
5/6/2020
– First quarter marked by positive results from AEZS-130-P01 (“Study P01”), of macimorelin, providing clinical framework to advance pediatric investigation plan (“PIP”) for macimorelin as a growth hormone deficiency diagnostic – – Planned safety and efficacy study AEZS-130-P02 (“Study P02”) of macimorelin expected to commence in Q4 2020 – – Advancing ongoing business development discussions to secure a commercialization partner for macimorelin in Europe and other key global markets –
-
Aeterna Zentaris to Present at the April 2020 Virtual Investor Summit– Presentation with live audio webcast on Thursday, April 23 at 10:00 AM ET, immediately followed by an interactive Q&A session –
4/15/2020
Aeterna Zentaris Inc. , today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris will present at the April 2020 Virtual Investor Summit on Thursday, April 23, 2020 at 10:00 AM ET. A live audio webcast of the presentation will be ava
-
Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing
4/15/2020
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that on April 8, 2020, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum $1.00 per share b
-
Aeterna Zentaris Announces EMA Decision To Accept A Modification To An Agreed Pediatric Investigation Plan For Macimorelin
4/7/2020
Modifications to the outline of Study P02 requested to ensure a harmonized global study protocol complying with requirements from EMA as well as FDA
-
AETERNA ZENTARIS ANNOUNCES POSITIVE RESULTS IN DOSE-FINDING PEDIATRIC STUDY OF MACIMORELIN
4/6/2020
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced positive results for the first pediatric study of macimorelin as a growth hormone stimulation test for the evaluation of child-onset growth hormone deficiency (“CGHD”).
-
AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE
3/30/2020
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today reported its financial and operating results for the fourth quarter and year ended December 31, 2019.
-
AETERNA ZENTARIS ANNOUNCES SETTLEMENT OF PREVIOUSLY DISCLOSED CLASS-ACTION LAWSUIT
3/12/2020
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced it has settled the previously disclosed class-action lawsuit against it pending in the U.S. District Court for the District of New Jersey.
-
Aeterna Zentaris Announces Closing of $4.5 Million Registered Direct Offering Priced At-The-Market
2/21/2020
Aeterna Zentaris Inc. announced the closing of its previously announced registered direct offering with several institutional investors in the United States for 3,478,261 common shares, at a purchase price of $1.29375 per share, priced at-the-market under Nasdaq rules.
-
Aeterna Zentaris Announces $4.5 Million Registered Direct Offering Priced At-The-Market
2/20/2020
Aeterna Zentaris Inc. announced that it has entered into a securities purchase agreement with several institutional investors in the United States providing for the sale and issuance of approximately 3,478,261 common shares at a purchase price of $1.29375 per common share in a registered direct offering priced at-the-market under Nasdaq rules.
-
Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor ConferencePresentation on Monday, February 17th at 11:30 a.m. ET
2/12/2020
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at NobleCon16 - Noble Capital Markets’ 16th Annual Investor Conference on Monday, February 17th at 11:30 a.m. ET in Hollywood, Florida.
-
Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin
1/28/2020
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, today announced the successful completion of patient recruitment for the first pediatric study of macimorelin as a growth hormone stimulation test for the evaluation of growth hormone deficiency (“GHD”) in children.
-
Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing
1/27/2020
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (“Bid Price Rule”).
-
Aeterna Zentaris Receives NASDAQ Notification Regarding Minimum Bid Price Requirement
1/8/2020
Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
-
Aeterna Zentaris Announces Publication of GHD Management Guidelines
12/18/2019
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) is pleased to announce that the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) have recently published the new ‘Guidelines for Management of Growth Hormone Deficiency in Adults and Patients transitioning from Pediatric to Adult Care’.